Inobo Therapeutics Approved for Preliminary KOSDAQ Listing Review
Inobo Therapeutics is embarking on the full-scale process of listing on the KOSDAQ market.
On October 16, Inobo Therapeutics said it had received approval from the Korea Exchange for its preliminary KOSDAQ listing review. The company plans to proceed with subsequent steps, including filing a securities registration statement, together with its lead underwriter, Korea Investment & Securities.
Founded in 2019, Inobo Therapeutics researches and develops synthetic drugs for immune and inflammatory diseases, fibrosis, and cancer, using DeepZema®, its artificial intelligence (AI) platform for drug discovery and development. By combining AI technology with drug development expertise, the company has built research and development capabilities spanning the discovery of drug candidates through clinical development.
The company currently has a total of 9 drug development pipelines, 4 of which have entered the clinical stage. In particular, it has built up research and development achievements by using its proprietary AI platform to discover drug candidates while advancing clinical development of its key pipelines.
With approval of its preliminary listing review, Inobo Therapeutics plans to accelerate clinical development of its key pipelines and strengthen the foundation for global technology transfers and the development of new pipelines. In particular, it aims to expand commercialization opportunities centered on drug candidates that have achieved clinical milestones.
Hot Picks Today
!["Samsung Electronics Employees Commute by Shuttle Bus"... More Than 5,000 Homes to Be Supplied in Seoul and Busan [Real Estate A to Z]](https://cwcontent.asiae.co.kr/asiaresize/93/2026092515334340873_1790318023.jpg)
"Samsung Electronics Employees Commute by Shuttle Bus"... More Than 5,000 Homes to Be Supplied in Seoul and Busan [Real Estate A to Z]
- A 12-Year-Old Girl Went to the Hospital After Her Blood Pressure Hit 225 and Was Stunned: "What Is This Coral Reef-Like Thing in Her Aorta?"
- Gyeongsangnam-do Selects 78 Participatory Budgeting Projects for 2027, Worth KRW 9.4 Billion
- "Hey, Lady, Teach Your Kids to Behave!" ... 300,000 Won in Cash and a Bodily Injury Claim Demanded Over Child's Door Ding
- "If This Airs, I'm Dead"... Why a Restaurant Refused to Let Jeon Hyunmoo's Show Film
“Approval of our preliminary listing review is an important step toward our IPO, backed by the AI-based drug development technology we have built up and the clinical and commercialization achievements of our key pipelines,” said Park Heedong, CEO of Inobo Therapeutics. “Through the listing, we will strengthen our research and development capabilities, expand clinical development of our key pipelines and global technology transfers, and establish a foundation for sustainable growth.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
